Organon 

$0
625
+$0+0% 今天

统计

当日最高
-
当日最低
-
52周高点
-
52周低点
-
成交量
-
平均成交量
-
市值
0
市盈率
-
股息率
-
股息
-

即将到来

财报

30Apr预期
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
下一步
0.63
0.76
0.88
1.01
预期EPS
0.828833
实际EPS
不适用

财务

13.49%利润率
有盈利
2019
2020
2021
2022
2023
2024
6.4B营收
864M净利润

分析师评级

$9.67平均目标价
最高预估为 12.00。
来自过去6个月内的 3 条评分。这不是投资建议。
买入
0%
持有
33%
卖出
67%

其他人也在关注

此列表基于在 Stock Events 上关注 OGN WI 的用户自选生成。这不是投资建议。

竞争对手

此列表为基于近期市场事件的分析。并非投资建议。

关于

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1
Show more...
首席执行官
Ms. Carrie Smith Cox
员工
10000
国家
GB

上市

0 Comments

分享你的想法

FAQ

Organon 的股票代码是什么?
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Organon 的股票以代码 OGN WI 进行交易。
Organon 下一次财报日期是什么时候?
Organon 将于 四月 30, 2026 发布下一次财报。
Organon 上一季度的财报怎么样?
OGN WI 上季度财报为每股 0.63 USD,预估为 0.73 USD,带来 -13.34% 的意外。下季度预估财报为每股 不适用 USD。
Organon 去年的营收是多少?
Organon 去年的营收为 6.4BUSD。
Organon 去年的净利润是多少?
OGN WI 去年的净收益为 864MUSD。
Organon 有多少名员工?
截至四月 06, 2026,公司共有10,000名员工。
Organon 何时完成拆股?
Organon 最近没有进行任何拆股。
Organon 的总部在哪里?
Organon 的总部位于 GB 的 Jersey City。